Raffles Medical Group

The hospital’s gestation losses from China cities will likely persist.

The private hospital group will see downside risks from lower TCF contributions. 

Singapore’s private hospital group seeks to acquire a majority interest.

The company attributed the increase to the return of foreign patients.

Elective surgery revival will benefit the hospital group.

Its target price was at $1.60.

Patient numbers had increased on the back of recovering medical tourism.

This is on the back of expected lower revenue from the hospital's COVID-19 services.

The group’s profits after tax ballooned by as much as 138.4%.

On back of higher patient load, clinic network expansion.

They rely on their group practice model.

On back of increased staff expenses.

It’s a year of integration and expansion for the firm.

There were fewer foreign patients in Q3.

Raffles Medical Group is looking to bounce by breaking into China this year. The Singapore-based health care provider, which operates dozens of medical clinics and laboratories as well as the Raffles Hospital, encountered a slight growth hiccup but it hopes to re-ignite its growth engine through an aggressive China expansion strategy. RFMD announced its collaboration with Shanghai Lujiazui to build a 300-bed hospital in Pudong, the bustling financial district in Shanghai, teeming with wealthy expats and a local population of more than 5 million. Raffles Medical has also agreed to work with China Merchant Group for a similar 200-bed hospital venture in Shenzhen, one of the country’s most successful Special Economic Zones situated just north of Hong Kong. Management is even considering building hospitals in the capital Beijing.